False-positive human T-lymphotropic virus serology after intravenous immunoglobulin transfusion

CMAJ. Canadian Medical Association Journal

Volumn 184, Issue 15, 2012, Pages 1709-1712

  Bélanger, Sophie Savary ^a   Fish, Douglas ^a,b   Kim, John ^c   Cohen, Sandra ^a,b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^c National Laboratory for HIV Reference Services   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84868128679     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.120019     Document Type: Article

References (6)

1. Circular of information for the use of labile blood products. LSC-SPE-006a Version 7. Québec (QC): Héma-Québec; 2010.
2. Plasma protein products information. Ottawa (ON): Canadian Blood Services. Available: www.bloodservices.ca/centreapps/internet/uwv502mainengine. nsf/page/EPlasmaProducts (accessed 2012 Jan. 5).
3. Constable SA, Parry CM, Enevoldson TP, et al. Positive serological tests for syphilis and administration of intravenous immunoglobulin. Sex Transm Infect 2007;83:57-8. (Pubitemid 46293807)
4. Rossi KQ, Nickel JR, Wissel ME, et al. Passively acquired treponemal antibody from intravenous immunoglobulin therapy in a pregnant patient. Arch Pathol Lab Med 2002;126:1237-8. (Pubitemid 36236620)
5. Arnold DM, Crowther MA, Meyer RM et al. Misleading hepatitis B test results due to intravenous immunoglobulin administration: implications for a clinical trial of rituximab in immune thrombocytopenia. Transfusion 2010;50:2577-81.
6. Kennedy GA, Cummings J, Durrant ST. Potential impact of AUSFTA on Australia's blood supply [letter]. Med J Aust 2007;186:427. (Pubitemid 46691868)